We’re excited to see our Ichthyosis community come together again!

📅 Saturday, January 17, 2026
📍 Lurie Children’s Hospital, Chicago

It’s a special chance to meet others living with Ichthyosis, hear updates on ongoing research, and enjoy some fun and support together.
We hope to see you there 💙

An Acid-Oxidising Solution Containing Hypochlorous Acid Reduces Staphylococcus aureus and Improves Bacterial Diversity in Epidermolysis Bullosa Wounds

#raredisease #epdermolysisbullosa #microbiome #dermsky #medsky

pubmed.ncbi.nlm.nih.gov/40803690/

New review article!
Deciding Which Patients With Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors

doi.org/10.1016/j.ja...

#dermsky #medsky

New Treatments in Atopic Dermatitis Update

#DermSky #MedSky
@annalsacaai.bsky.social

pubmed.ncbi.nlm.nih.gov/40562170/

Excited to share that three of our lab members are presenting their work at # #SIDSanDiego25! Come support them at their talks and poster sessions.
@siderm.bsky.social
#DermSky

Having a device that can measure TEWL remotely, continuously or as programmed by the investigator - and without perturbing a patient during sleep - is a major advance.

#wearabledevices #DermSky

A non-contact wearable device for monitoring epidermal molecular flux
www.nature.com/articles/s41...

A new classification of hereditary EDDs highlights shared disease mechanisms—unlocking targeted, pathogenesis-based treatments. From lovastatin-cholesterol to kallikrein inhibitors and gene editing, care for syndromic ichthyosis is evolving.
doi.org/10.1093/bjd/...

#raredisease #MedSky #DermSky

Long-term dupilumab treatment in young children (6mo–5y) with moderate-to-severe AD shows low infection rates. This reinforces its strong safety profile for pediatric eczema care.

#AtopicDermatitis #Dupilumab #PediatricDermatology #medsky #dermsky

Read more: eprints.whiterose.ac.uk/220380/

New study on tapinarof cream 1% in pediatric AD! Minimal systemic absorption, favorable safety, and good tolerability in children (2–17 yrs)with extensive AD. The treatment was well tolerated, even on sensitive skin and flexural areas, with only mild folliculitis reported. #atopicdermatitis #dermsky

Great to be at #AAD2025, sharing our lab’s work and connecting with colleagues in the field. Exciting discussions and a fantastic meeting!
Science drives innovation, informs policy, and improves lives—let’s continue to champion its role in society.

#StandUpForScience
@aadmember.bsky.social

So proud of our amazing faculty in skin research - consistently at the top and this year #2. Go Northwestern Dermatology!

#DermSky
#MedSky

Debra and @charitydebra.bsky.social are delighted to support a clinical trial led by @pallerlab.bsky.social @nufeinbergmed.bsky.social.

The trial explores #repurposing Dupilumab - used for eczema - to treat itch, blistering, and pain in all types of #EB.

Read more 👉 bit.ly/Dupilumabtot...

Great to see some action in addressing the curtailing of science

#MedSky #DermSky #ScienceSky #StandUpForScience2025

Excited about a device that both measures scratch based on finger movement and the sound of itch — and can optionally provide a haptic vibration when sensing scratch to stop it, even at night. 

pubmed.ncbi.nlm.nih.gov/39908036/

ISPD Webinar on Neonatal dermatology

Saturday, 15 February
8 AM Eastern Standard Time (EST)
London: 1 PM | Dubai: 5 PM | Perth: 9 PM

Register:
www.ispedderm.com/webinar-1-ne...

Biologics in congenital ichthyosis: are they effective?

doi: 10.1093/bjd/ljae420

pubmed.ncbi.nlm.nih.gov/39470394/

"Biologics may lead to improvement in only a subset of patients with congenital ichthyoses with only some of them noting a good response."

Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry

pubmed.ncbi.nlm.nih.gov/39623757/

#atopicdermatitis #dermatology

www.drugdiscoverynews.com/old-drugs-sh...

#raredisease #dermatology #ichthyosis